AsOf

Recorded or changed on this day 2026-11-08

4,701–4,750 of 46,575 claims, by entity. Everything on 2026-11-08 →

superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
Arista Networks · cash and equivalents · 2,092,101,000 United States dollar
Arista Networks cash and equivalents: 2,092,101,000 United States dollar, claim clm_FC3A4C2A7060 · ended · superseded by clm_F2B8ED9EB611 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
Arista Networks · operating income · 149,308,000 United States dollar
Arista Networks operating income: 149,308,000 United States dollar, claim clm_FE13F3D5BE2B · ended · superseded by clm_F6EFE215AA09 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
Arista Networks · total assets · 4,111,845,000 United States dollar
Arista Networks total assets: 4,111,845,000 United States dollar, claim clm_FEBE6F0B2D37 · ended · superseded by clm_B82A9CDA6F57 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
Arista Networks · total assets · 19,448,600,000 United States dollar
Arista Networks total assets: 19,448,600,000 United States dollar, claim clm_FF78BFBB0B01 · ended · superseded by clm_6893443E6835 · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
Arkady Volozh · founder of · Yandex
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
Arkady Volozh · CEO of · Yandex
Arkady Volozh CEO of: Yandex, claim clm_D5DD132B809A · valid · 5 sources (2 primary) · conf 0.85
unverified: One source so far: shown on the record, not asserted, until a second source or a primary one confirms it.
unverified: One source so far: shown on the record, not asserted, until a second source or a primary one confirms it.
Arvind Krishna · chair of · IBM
Arvind Krishna chair of: IBM, claim clm_286790F03D3E · new claim · 1 source · conf 0.60
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
Arvind Krishna · CEO of · IBM
Arvind Krishna CEO of: IBM, claim clm_895944410998 · valid · 3 sources · conf 0.90
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
Askul Corporation · headquarters · Toyosu
Askul Corporation headquarters: Toyosu, claim clm_2FF99874607D · valid · 3 sources (2 primary) · conf 0.80
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
ASML · subsidiary · ASML Berlin
ASML subsidiary: ASML Berlin, claim clm_692CA5F9F873 · valid · 2 sources (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total assets · 61,377,000,000 United States dollar
AstraZeneca total assets: 61,377,000,000 United States dollar, claim clm_010DB2BB1408 · ended · superseded by clm_BFC9DC65FD19 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · revenue · 24,384,000,000 United States dollar
AstraZeneca revenue: 24,384,000,000 United States dollar, claim clm_08D5EE5A62C8 · ended · superseded by clm_85B6D134E13C · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · operating income · 3,387,000,000 United States dollar
AstraZeneca operating income: 3,387,000,000 United States dollar, claim clm_0928C69F436C · ended · superseded by clm_CA91157E8FEC · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total assets · 63,354,000,000 United States dollar
AstraZeneca total assets: 63,354,000,000 United States dollar, claim clm_10CF439A8D3D · ended · superseded by clm_39BC161464CE · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · operating income · 1,056,000,000 United States dollar
AstraZeneca operating income: 1,056,000,000 United States dollar, claim clm_10DEC07C1593 · ended · superseded by clm_F928384EA602 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · net income · 3,406,000,000 United States dollar
AstraZeneca net income: 3,406,000,000 United States dollar, claim clm_194B34501880 · ended · superseded by clm_7BDCCD2AEF61 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · revenue · 45,811,000,000 United States dollar
AstraZeneca revenue: 45,811,000,000 United States dollar, claim clm_1A1A4ACC29CB · ended · superseded by clm_5BDDB85A5719 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 19,646,000,000 United States dollar
AstraZeneca total equity: 19,646,000,000 United States dollar, claim clm_1A634ECF5C3D · ended · superseded by clm_4F3F4354CA13 · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · SIC industry · Pharmaceutical Preparations (2834)
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · revenue · 44,351,000,000 United States dollar
AstraZeneca revenue: 44,351,000,000 United States dollar, claim clm_31557855C15A · ended · superseded by clm_1A1A4ACC29CB · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · total equity · 48,719,000,000 United States dollar
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · operating income · 10,003,000,000 United States dollar
AstraZeneca operating income: 10,003,000,000 United States dollar, claim clm_3994638C1B14 · ended · superseded by clm_763AA2791DE9 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total assets · 60,651,000,000 United States dollar
AstraZeneca total assets: 60,651,000,000 United States dollar, claim clm_39BC161464CE · ended · superseded by clm_010DB2BB1408 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total assets · 60,056,000,000 United States dollar
AstraZeneca total assets: 60,056,000,000 United States dollar, claim clm_39CC74EC0018 · ended · superseded by clm_4B2074B77E0B · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · listed on · NYSE
AstraZeneca listed on: NYSE, claim clm_43376D897A1F · valid · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · fiscal year end · 12-31
AstraZeneca fiscal year end: 12-31, claim clm_433F982364C7 · valid · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · revenue · 37,417,000,000 United States dollar
AstraZeneca revenue: 37,417,000,000 United States dollar, claim clm_47272A7D1B25 · ended · superseded by clm_31557855C15A · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total assets · 62,526,000,000 United States dollar
AstraZeneca total assets: 62,526,000,000 United States dollar, claim clm_4B2074B77E0B · ended · superseded by clm_10CF439A8D3D · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 18,509,000,000 United States dollar
AstraZeneca total equity: 18,509,000,000 United States dollar, claim clm_4F3F4354CA13 · ended · superseded by clm_B272D51F85BC · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 14,044,000,000 United States dollar
AstraZeneca total equity: 14,044,000,000 United States dollar, claim clm_4F65B3C1FC28 · ended · superseded by clm_7E8748E6B574 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 39,287,000,000 United States dollar
AstraZeneca total equity: 39,287,000,000 United States dollar, claim clm_515C40C5227C · ended · superseded by clm_CC377A6E41D1 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · net income · 1,227,000,000 United States dollar
AstraZeneca net income: 1,227,000,000 United States dollar, claim clm_529E4815C0D2 · ended · superseded by clm_B737A429D7E9 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · revenue · 54,073,000,000 United States dollar
AstraZeneca revenue: 54,073,000,000 United States dollar, claim clm_5BDDB85A5719 · ended · superseded by clm_75285D1846DF · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · registrant name · ZENECA GROUP PLC
AstraZeneca registrant name: ZENECA GROUP PLC, claim clm_5C035E7A6F9A · ended · superseded by clm_CC0A4381A0A0 · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · CEO · Pascal Soriot
AstraZeneca CEO: Pascal Soriot, claim clm_5E921CD2E098 · valid · 3 sources (2 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · operating income · 4,902,000,000 United States dollar
AstraZeneca operating income: 4,902,000,000 United States dollar, claim clm_654CC8AE2812 · ended · superseded by clm_77DE63410430 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 16,642,000,000 United States dollar
AstraZeneca total equity: 16,642,000,000 United States dollar, claim clm_6A3694B18261 · ended · superseded by clm_4F65B3C1FC28 · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · headquarters · Cambridge
AstraZeneca headquarters: Cambridge, claim clm_6B4DC8E0E36A · valid · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 40,871,000,000 United States dollar
AstraZeneca total equity: 40,871,000,000 United States dollar, claim clm_702A322E3B09 · ended · superseded by clm_327B10FB292B · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · revenue · 58,739,000,000 United States dollar
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · operating income · 13,743,000,000 United States dollar
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · operating income · 3,677,000,000 United States dollar
AstraZeneca operating income: 3,677,000,000 United States dollar, claim clm_77DE63410430 · ended · superseded by clm_0928C69F436C · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · revenue · 22,090,000,000 United States dollar
AstraZeneca revenue: 22,090,000,000 United States dollar, claim clm_790001197E10 · ended · superseded by clm_08D5EE5A62C8 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · net income · 2,868,000,000 United States dollar
AstraZeneca net income: 2,868,000,000 United States dollar, claim clm_7BDCCD2AEF61 · ended · superseded by clm_80CF1A157103 · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · total equity · 14,596,000,000 United States dollar
AstraZeneca total equity: 14,596,000,000 United States dollar, claim clm_7E8748E6B574 · ended · superseded by clm_F30C48EE7B4A · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · operating income · 8,193,000,000 United States dollar
AstraZeneca operating income: 8,193,000,000 United States dollar, claim clm_7E98BE75827B · ended · superseded by clm_3994638C1B14 · 1 source (1 primary) · conf 0.95
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · net income · 10,233,000,000 United States dollar
valid: Two independent sources agree, or a primary source states it: the record asserts this claim, unless it is a post, is marked for review or carries a confidence below 0.5.
AstraZeneca · ticker · AZN
AstraZeneca ticker: AZN, claim clm_7F36A4D2B72F · valid · 1 source (1 primary) · conf 0.95
superseded: A later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.
AstraZeneca · net income · 2,050,000,000 United States dollar
AstraZeneca net income: 2,050,000,000 United States dollar, claim clm_80CF1A157103 · ended · superseded by clm_529E4815C0D2 · 1 source (1 primary) · conf 0.95

What the statuses mean